Trial Search Results
Feasibility Study of New Method of Diagnostic and Prediction of Painful CIPN
This clinical trial studies how well Diode laser fiber type Selective Stimulator (DLss) works in predicting pain development in patients with ovarian cancer who are receiving chemotherapy. Stimulating of the pain nerve fibers in the skin with laser light stimulation may help to predict whether a patient will develop painful peripheral neuropathy, correlate with the severity of neuropathy during and after chemotherapy treatment, and may help to explain the mechanisms of chemotherapy-induced neuropathic pain (CIPN).
Stanford is currently accepting patients for this trial.
- Diagnostic Test: Diode Laser fiber type Selective Stimulator (DLss)
- Pathologically-proven ovarian cancer, or cancer of mullerian origin, that was or will
be treated with a 1st-line taxane plus a platinum-based chemotherapy regimen.
- GROUP A (painful neuropathy group): Subjective symptoms of painful peripheral
neuropathy (burning, stabbing, throbbing, painful tingling, aching in the fingers
and/or toes) that is greater than or equal to 10 on a scale of 0 to 100 in the
neuropathic pain questionnaire
- GROUP B (painless neuropathy group): Subjective symptoms of painless neuropathy (loss
of sensation, worsening balance, strange sensation in fingers and/or toes) or no
complaints related to neuropathy.
- Life expectancy of 6 months
- Ability to understand the study protocol, participate in testing, and the willingness
to sign a written informed consent document.
- Received prior chemotherapy for ovarian cancer or cancer of mullerian origin other
than 1st-line treatment with a taxane + platinum based regimen.
- No concurrent investigational drugs.
- Received investigational drugs suspected to cause peripheral neuropathy.
- History of B12 deficiency
- History of neuropathy or numbness/tingling suspicious for neuropathy, prior to the
first dose of chemotherapy for ovarian cancer
- Prior treatment for other cancers that included drugs known to cause neuropathy
(including but are not limited to vinca-alkaloids, platinums, taxanes, bortizomib).
- Known peripheral vascular disease
- Chronic daily headache or headache for more than 14 days of the month
- Pain rated 50 or higher on a scale of 0 to 100, with 0 = no pain at all and 100 =
worst pain imaginable.
- Pregnant or nursing
- Do not speak or read English
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study